Gastroparesis on Mounjaro: What Delayed Stomach Emptying Really Means

Gastroparesis on Mounjaro is one of the most searched safety concerns among patients starting tirzepatide for weight loss, and recent media coverage has raised the alarm further. Headlines about “stomach paralysis” can be frightening, but the clinical reality is considerably more nuanced than most reports suggest.

This guide explains what gastroparesis actually is, how it differs from the normal gastric slowing that makes Mounjaro effective, what the trial data show about tirzepatide specifically, and when you should speak to your doctor. If you are experiencing nausea or vomiting on Mounjaro, our separate guide on managing nausea on Mounjaro offers practical dietary advice.

True gastroparesis, a chronic condition in which the stomach cannot empty properly, has been reported in fewer than 0.1 per cent of tirzepatide patients across all published clinical trials. The far more common experience is temporary delayed gastric emptying, which is an expected and intentional part of how GLP-1 receptor agonists work. This slowing is what reduces appetite, helps you feel full sooner, and supports weight loss.

Both the MHRA and the FDA continue to list gastrointestinal effects as known side effects of tirzepatide, but neither agency has issued warnings specifically linking Mounjaro to chronic gastroparesis. A 2025 pharmacovigilance analysis found no gastroparesis reports linked to tirzepatide in adverse event databases, unlike semaglutide.

Gastroparesis is a chronic motility disorder in which the stomach muscles fail to contract normally, leading to food remaining in the stomach for hours or even days. Symptoms include persistent nausea, vomiting of undigested food, early satiety, bloating, and abdominal pain. It is typically diagnosed using a gastric emptying study, which measures how quickly a standardised meal leaves the stomach.

Delayed gastric emptying, by contrast, is a pharmacological effect. When you take tirzepatide, the medication activates GLP-1 and GIP receptors in the gut, deliberately slowing the rate at which food moves from the stomach into the small intestine. This is not a malfunction. It is part of the drug’s mechanism of action and one of the reasons patients feel satisfied with smaller portions.

The distinction matters because delayed gastric emptying caused by Mounjaro is dose-dependent, usually temporary during the early weeks of treatment, and resolves when the medication is stopped. True gastroparesis is a structural or neurological condition that persists independently of medication use.

Pharmacodynamic studies have confirmed that tirzepatide produces dose-dependent slowing of gastric emptying, with the effect being most pronounced during the initial weeks of treatment. Importantly, this slowing shows attenuation over time with continued use, meaning your stomach adjusts as treatment progresses.

In the SURMOUNT clinical trial programme, which evaluated tirzepatide for weight management in patients without type 2 diabetes, approximately 80 to 90 per cent of gastrointestinal adverse events occurred during the dose escalation period. Most resolved within four to eight weeks without requiring treatment discontinuation.

A pooled analysis of the SURMOUNT-1 through SURMOUNT-4 trials published in Diabetes, Obesity and Metabolism in 2025 found that gastrointestinal tolerability was generally consistent across the programme. Nausea, the most commonly reported symptom, affected roughly 24 to 33 per cent of participants at higher doses but led to treatment discontinuation in only 4 to 7 per cent of cases.

No cases of confirmed chronic gastroparesis were attributed to tirzepatide in any of the pivotal trials. The JAMA study that received widespread media coverage in early 2026, which reported a 3.67-fold increased risk of gastroparesis among GLP-1 users, pooled all GLP-1 receptor agonists together and did not distinguish between tirzepatide and older medications. When tirzepatide-specific data are examined separately, the signal is not present.

Tirzepatide is a dual GLP-1 and GIP receptor agonist, which distinguishes it from single-target GLP-1 medications such as semaglutide and liraglutide. The GIP receptor activation appears to modulate gastrointestinal motility differently, potentially explaining the more favourable gastroparesis profile observed in pharmacovigilance data.

A 2025 analysis of the FDA Adverse Event Reporting System (FAERS) found zero gastroparesis reports linked to tirzepatide, while semaglutide and liraglutide both had documented cases. While post-marketing surveillance has limitations and absence of reports does not guarantee absence of risk, this finding is reassuring when considered alongside the clinical trial data.

Head-to-head comparisons between tirzepatide and semaglutide for gastroparesis risk specifically are limited, and more long-term data will be needed to confirm these early observations.

Most patients on Mounjaro will experience some degree of appetite reduction, early fullness, or mild nausea during the first few weeks of treatment. These are expected effects and do not indicate gastroparesis.

You should contact your prescribing clinician or seek medical attention if you experience vomiting that persists for more than 48 hours and does not respond to dietary adjustments, an inability to keep down any food or liquids, severe abdominal pain or visible distension, unintentional weight loss that is significantly faster than your treatment plan anticipated, or symptoms that worsen rather than improve as you continue at the same dose.

At CutKilo, our doctors monitor your progress at each check-in and can slow your dose escalation schedule if gastrointestinal symptoms are more than mild. Pausing at a lower dose for an additional two to four weeks often resolves symptoms without needing to stop treatment entirely.

The most effective strategy is gradual dose escalation. Tirzepatide is designed to be titrated slowly, starting at 2.5 mg and increasing every four weeks. Skipping doses or escalating faster than recommended significantly increases the likelihood of gastrointestinal side effects.

Eating smaller, more frequent meals rather than large portions helps your stomach manage the slower emptying rate. High-fat and high-fibre meals take longer to digest under normal circumstances, and this effect is amplified on Mounjaro. Lean protein, cooked vegetables, and moderate portion sizes are generally best tolerated during the early weeks.

Staying well hydrated is important because vomiting or reduced food intake can lead to dehydration, which worsens nausea. Sipping water throughout the day rather than drinking large volumes at meals tends to be better tolerated.

If you are scheduled for surgery or a procedure requiring general anaesthesia, inform your anaesthetist that you are taking tirzepatide. Our guide on Mounjaro before surgery covers the specific precautions your medical team should take regarding delayed gastric emptying and aspiration risk.

Several high-profile lawsuits filed in the United States in 2025 and 2026 allege that manufacturers of GLP-1 receptor agonists failed to adequately warn patients about the risk of gastroparesis. These cases have generated significant media attention, and it is understandable that patients may feel concerned.

It is worth noting that the majority of these legal actions relate to older GLP-1 medications and to cases where patients were not under regular medical supervision. The lawsuits do not constitute clinical evidence of a causal link, and regulatory agencies including the FDA, MHRA, and EMA have not changed their prescribing guidance for tirzepatide as a result of these proceedings.

Supervised, doctor-led weight loss programmes such as CutKilo’s, where dose escalation is carefully managed and patients are monitored throughout treatment, represent a fundamentally different risk profile from unsupervised use or off-label prescribing.

Is gastroparesis from Mounjaro permanent? In the rare cases where significant gastric slowing has been reported with GLP-1 medications, the effect has been reversible upon stopping the medication. True permanent gastroparesis from tirzepatide has not been documented in clinical trials.

How common is gastroparesis on Mounjaro? Chronic gastroparesis has been reported in fewer than 0.1 per cent of patients in tirzepatide clinical trials, and a 2025 pharmacovigilance analysis found no tirzepatide-specific gastroparesis reports in adverse event databases. Temporary delayed gastric emptying, which is mild and self-limiting, is far more common.

Should I stop Mounjaro if my stomach feels slow? Feeling full more quickly and eating smaller portions is an expected and beneficial effect of the medication. Do not stop treatment without consulting your prescriber. If symptoms are uncomfortable, your doctor can hold your current dose for longer before escalating.

Does Mounjaro slow gastric emptying more than Ozempic? Both medications slow gastric emptying as part of their mechanism. Early pharmacovigilance data suggest tirzepatide may have a more favourable gastroparesis profile than semaglutide, though head-to-head comparisons for this specific outcome are limited.

Can I take Mounjaro if I already have gastroparesis? If you have a pre-existing diagnosis of gastroparesis, tirzepatide may not be appropriate for you. Your CutKilo doctor will review your full medical history before prescribing and can discuss alternative approaches if needed.

The distinction between delayed gastric emptying and true gastroparesis is critical for understanding the safety of Mounjaro. Slowed stomach emptying is part of how tirzepatide works, and it is what helps you eat less and lose weight. True gastroparesis remains exceptionally rare in clinical trial data, and tirzepatide-specific pharmacovigilance data are more reassuring than for older GLP-1 medications. Under proper medical supervision with gradual dose escalation, the risk is very low, and the vast majority of gastrointestinal symptoms resolve within the first weeks of treatment.